The first non-invasive biomarker to track and verify efficacy of senolytic drugs
Researchers have discovered a novel, non-invasive biomarker (15-deoxy-delta-12, 14-prostaglandin J2; dihomo-15d-PGJ2) that can be used to measure & track performance of senolytics: a class of drugs that selectively eliminate senescent cells.
https://medicalxpress.com/news/2021-04-non-invasive-biomarker-track-efficacy-senolytic.html